Laura E. Niklason - Dec 16, 2022 Form 4 Insider Report for Humacyte, Inc. (HUMA)

Role: President, CEO and Director, Director, 10%+ Owner
Signature: /s/ Laura E. Niklason by Dale A. Sander as Attorney-in-Fact
Stock symbol: HUMA
Transactions as of: Dec 16, 2022
Transactions value $: -$606,031
Form type: 4
Date filed: 12/19/2022, 07:23 PM
Previous filing: Dec 19, 2022
Next filing: Mar 2, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	HUMA	Common Stock	Sale	-$606K	-240K	-1.31%	$2.53	18M	Dec 16, 2022	By Ayabudge LLC	F1, F2
holding	HUMA	Common Stock						1.16M	Dec 16, 2022	Direct
holding	HUMA	Common Stock						510K	Dec 16, 2022	By spouse

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for the purchasers to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Mr. Dougan, directly and indirectly, remains the largest shareholder of the Issuer. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly owned by Dr. Niklason were sold in these transactions.
F2	The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $2.50 to $2.63. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Content

The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for the purchasers to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Mr. Dougan, directly and indirectly, remains the largest shareholder of the Issuer. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly owned by Dr. Niklason were sold in these transactions.

The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $2.50 to $2.63. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.